Citalopram
(R)-(−)-citalopram (top), (S)-(+)-citalopram (bottom) | |
| Clinical data | |
|---|---|
| Pronunciation | /saɪˈtæləˌpræm, sɪ-/; sy-TA-lə-pram |
| Trade names | Celexa, Cipramil, others |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a699001 |
| License data |
|
| Pregnancy category |
|
| Dependence liability | Low |
| Routes of administration | oral, intravenous |
| Drug class | Selective serotonin reuptake inhibitor (SSRI) |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 80% peak at 4 hours |
| Protein binding | <80% |
| Metabolism | Liver (CYP3A4 and CYP2C19) |
| Metabolites | Desmethylcitalopram (DCT) and didesmethylcitalopram (DDCT) |
| Elimination half-life | 35 hours |
| Excretion | Mostly as unmetabolized citalopram, partly DCT, and traces of DDCT in urine |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.056.247 |
| Chemical and physical data | |
| Formula | C20H21FN2O |
| Molar mass | 324.399 g·mol−1 |
| 3D model (JSmol) | |
| Chirality | Racemic mixture |
| |
| |
| (verify) | |
Citalopram, sold under the brand name Celexa among others, is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It is used to treat major depressive disorder, obsessive–compulsive disorder, panic disorder, and social anxiety disorder. The antidepressant effects may take one to four weeks to occur. It is typically taken orally (swallowed by mouth). In some European countries, it is sometimes given intravenously (injected into a vein) to initiate treatment, before switching to the oral route of administration for continuation of treatment. It has also been used intravenously in other parts of the world in some other circumstances.
Common side effects include nausea, trouble sleeping, sexual problems, shakiness, feeling tired, and sweating. In some patients, sexual dysfunction may persist even after the drug is discontinued, a condition known as post-SSRI sexual dysfunction; regulatory agencies including the European Medicines Agency and Health Canada have recommended that citalopram's product labeling warn of this risk. Serious side effects include an increased risk of suicide in those under the age of 25, serotonin syndrome, glaucoma, and QT prolongation.
Citalopram was approved for medical use in the United States in 1998. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication. In 2023, it was the 43rd most commonly prescribed medication in the United States, with more than 14 million prescriptions.